Transferred T helper cell sorted from mice
Ontology highlight
ABSTRACT:
ORGANISM(S): Mus musculus
PROVIDER: GSE97087 | GEO | 2017/08/10
SECONDARY ACCESSION(S): PRJNA380666
REPOSITORIES: GEO
Similar Datasets
Project description:Expression prolile of CWHM-823+tGro-b mobilized (3 mg/kg + 2.5 mg/kg, s.c. injection, timepoint 30 min) HSPC was compared to that of AMD3100 (5 mg/kg, 1 hr after s.c. injection) or G-CSF (100 ug/kg/injection, q12h, 5 days) mobilized as well as BM resident HSPC. Accordingly, the cells were isolated from the BM of untreated or from the peripheral blood (PB) of differentially mobilized mice.
2018-12-08 | GSE123505 | GEO
Project description:We report that the Th9 differenciation program is boosted in presence of Il-1beta Examination of the expression profile of Th9 CD4+ T cells after 1 hour and 3 days of differentiation and after in vivo injection
2014-05-23 | E-GEOD-54697 | biostudies-arrayexpress
Project description:Mouse models of ovarian cancer commonly involve tumor cell transfer into the peritoneal cavity to establish metastatic disease. However, once disease has become established and disseminated through the abdomen, surgical cytoreduction in mice is not feasible. We set out to develop an ovarian cancer model amenable to surgical cytoreduction to mimic clinical treatment paradigms.
2020-04-25 | GSE149320 | GEO
Project description:T helper 9 (TH9) cells are important for the development of inflammatory and allergic diseases. The TH9 transcriptional network converge signals from cytokines and antigen presentation but is incompletely understood. Here, we identified TL1A, a member of the TNF superfamily, as strong inducer of mouse and human TH9 differentiation. Mechanistically, TL1A induced the expression of the transcription factors BATF and BATF3 and facilitated their binding to the Il9 promoter leading to enhanced secretion of IL-9. BATF- and BATF3-deficiencies impaired IL-9 secretion under TH9 and TH9-TL1A polarizing conditions. In vivo, using a T cell transfer model we demonstrated that TL1A promoted IL-9-dependent, TH9 cell-induced intestinal and lung inflammation. Neutralizing IL-9 antibodies attenuated TL1A-driven mucosal inflammation. Batf3-/- TH9-TL1A cells induced reduced inflammation and cytokine expression in vivo compared to WT cells. Our results demonstrate that TL1A promotes TH9 cell differentiation and function and define a role of BATF3 in TH9-induced mucosal inflammation.
2019-01-08 | GSE106926 | GEO
Project description:we performed proteome analysis of Th9 cells to understand the involvement of proteins that might be crucial for the anti-tumor functions of Th9 cells. Here we show for the first time a comprehensive proteomic analysis of murine Th0 and Th9 cells, which identified 1451 total proteins among which 1367 proteins were common. Further analysis revealed that 118 proteins were upregulated while 81 proteins were downregulated in Th9 cells. Pathway analysis suggested an abundance of phosphoproteins in the proteome of Th9 cells. Among upregulated phosphoproteins which showed to be involved in immune 34 system, Ppp2ca (catalytic subunit of protein phosphatase, PP2A) was found to be highly expressed in Th9 cells. Although the role of PP2A has been shown to regulate the differentiation and functions of Th1,Th2, Th17 and Tregs, its role in differentiation and functions of Th9 cells is not identified yet. Our results show for the first time that PP2A is required for the differentiation and anti-tumor functions of Th9 cells. PP2A inhibition leads to the suppression of IL-9 induction and the expression of key transcription factors of Th9 cells.
2021-09-09 | PXD019506 | Pride
Project description:We recently reported that tumor-specific Th9 cells are less susceptible to exhaustion, fully cytolytic to tumor cells, and possess long-term persistence capacity because of their unique hyperproliferative T cell feature. However, these observations only revealed how tumor-specific Th9 cells eradicate antigen-positive tumor cells. Given the unmet need to develop effective ACT strategies with tumor-specific Th9 cells for solid tumors with the heterogeneity in antigen expression, the CD11b+CD11c–Ly6Chi inflammatory monocytes were flow-sorted from Th9 treated mice, and been further analyzed for microarray.
2020-06-08 | GSE151712 | GEO
Project description:Interleukin 9 (IL-9)-producing helper T (Th9) cells are essential for inducing anti-tumor immunity and inflammation in allergic and autoimmune diseases. Although transcription factors that are essential for Th9 cell differentiation have been identified, other signaling pathways that are required for their generation and functions are yet to be found. Here we identified that Epidermal Growth Factor Receptor (EGFR) is essential for IL-9 induction in Th cells. Moreover, amphiregulin (Areg), an EGFR ligand, is critical for the amplification of Th9 cells induced by TGF-β1 and IL-4. Furthermore, our data show that AREG-EGFR signaling induces HIF1α, which binds and transactivates IL-9, IRF4 and NOS2 promoters in Th9 cells. Loss of EGFR or HIF1α abrogates Th9 cell differentiation and suppress their anti-tumor functions. Moreover, in line with its reliance on HIF1α expression, metabolomics profiling of Th9 cells revealed that succinate, a TCA cycle metabolite, promotes Th9 cell differentiation and Th9 cell-mediated tumor regression.
2021-06-15 | GSE163056 | GEO
Project description:Radiotherapy is standard of care for inoperable non-small cell lung cancers (NSCLC) but adenocarcinoma NSCLC respond more poorly than squamous cell NSCLC. Transforming growth factor β (TGFβ) activity is induced by radiation and plays a recently recognized role in the DNA damage response. Here we show in murine lung tumor model that radiation activates TGFβ acutely and persistently and that TGFβ neutralizing antibody, 1D11, systemic treatment increased tumor control following either fractionated or single high dose radiation regimes. TGFβ dependent genes in the irradiated tumor indicated crosstalk between innate and adaptive immunity but therapeutic benefit of 1D11 in irradiated tumors in immunocompromised mice suggested that innate immune cells are more influential than the adaptive immune response. Irradiated tumors in which TGFβ was blocked were highly hypoxic, exhibit pronounced microvascular damage and promoted neither cancer-associated fibroblasts nor recruit bone marrow derived cells (BMDC). Tumor educated immature BMDC were significant sources of TGFβ and inhibiting BMDC recruitment achieved tumor growth control in response to RT comparable to TGFβ inhibition. Thus, radiation-induced TGFβ both compromises tumor control by RT and promotes reestablishment of the tumor microenvironment. Concordant with the critical role of TGFβ activity in RT, radiation resistant NSCLC adenocarcinomas exhibit higher TGFβ activity compared to squamous cell NSCLC, which suggests a rationale for using TGFβ inhibition to augment radiotherapy. Lewis lung cancer (LLC) model were established in 6 to 8 week-old C57BL/6 female mice by subcutaneous injection. When tumors were 60-80 mm3, Mice were randomized to achieve comparable mean tumor size for each treatment group as indicated below. Tumor growth were monitored and tumors were collected and characterized by gene expression profiling and immunostaining.
2015-12-15 | E-GEOD-73095 | biostudies-arrayexpress
Project description:To identify factors preferentially necessary to drive tumor expansion we performed parallel in vitro and in vivo negative selection shRNA screens. Melanoma cells harboring shRNAs targeting several DNA Damage Response (DDR) kinases had a greater selective disadvantage in vivo than in vitro, indicating an essential contribution of these factors during tumor expansion. In growing tumors, DDR kinases were activated following hypoxia. Correspondingly, depletion or pharmacologic inhibition of DDR kinases was toxic to melanoma cells, including those that were resistant to BRAF inhibitor, and this could be enhanced by angiogenesis blockade. These results reveal that hypoxia sensitizes melanomas to targeted inhibition of the DDR and illustrate the utility of in vivo shRNA dropout screens for identification of pharmacologically tractable targets. A lentivirus-based kinome shRNA library (four pools) was used to transduce 888mel cells (MOI<0.2). After puromycin selection (1μg/ml), two reference samples were collected as controls. Next, tumor cells (5x105 per injection) were either injected s.c. into 6 NSG mice or plated into 6 independent plates (5x105) for in vitro culture. Tumors were removed from the mice and genomic DNA used to recover shRNAs by PCR amplification followed by deep sequencing. Three analyses were performed independently in parallel: (1) Tumors versus cultured cells (Log2 Fold Change < -1); (2) Tumors versus references (Log2 Fold Change < -2.5) and (3) Cultured cells versus references (Log2 Fold Change < -2.5). Genes targeted with at least 2 shRNAs in each of the analysis were considered hits with an enhanced in vivo effect.
2014-09-30 | E-GEOD-61826 | biostudies-arrayexpress
Project description:Casitas B lymphoma-b (Cbl-b) is a central negative regulator of cytotoxic T and NK cells, explaining its intracellular checkpoint function in cancer. Increasing evidence highlights the importance of CD4+ T helper cell populations (e.g., IL-9 producing T cells: Th9 cells) for anti-cancer immunity. We here provide experimental evidence that Cbl-b acts as rheostat favoring regulatory T cells (Treg) at the expense of Th9 cell differentiation. Adoptively transferred tumor-model antigen specific Cblb-/- Th9 cells exert superior anti-tumor activity leading to improved melanoma control in vivo. Accordingly, blocking IL-9 in melanoma cell-exposed Cblb-/- mice reverses their tumor rejection phenotype. Single cell RNA sequencing of in vitro differentiated Th9 cells from naïve T cells isolated from WT and Cblb-/- animals revealed the transcriptomic basis for increased Th9 cells differentiation. In summary, we here first establish IL-9 and Th9 cells as key anti-tumor executers in Cblb-/- animals. This knowledge may be helpful for future improvement of adoptive T cell therapies in cancer.
2022-04-30 | GSE173395 | GEO